Establishing a cardiology registry: navigating quality and regulatory challenges with a focus on congenital heart disease
- PMID: 40385276
- PMCID: PMC12082178
- DOI: 10.21037/cdt-2024-579
Establishing a cardiology registry: navigating quality and regulatory challenges with a focus on congenital heart disease
Abstract
Registries have become pivotal in medical research, offering a robust foundation for understanding disease incidence, treatment patterns, and patient outcomes across diverse populations. By aggregating real-world data (RWD), registries provide invaluable insights into real-world evidence (RWE), shaping clinical guidelines, healthcare policies, and regulatory decisions. Their widespread acceptance underscores their scientific validity and their role in driving evidence-based medicine, ultimately improving healthcare outcomes. In cardiology, particularly within the specialized field of congenital heart disease (CHD), national and international registries have emerged as indispensable tools. They enable the systematic collection of data on patient demographics, disease progression, therapeutic interventions, and long-term outcomes. These datasets support a range of purposes, including observational studies, quality improvement initiatives, and regulatory assessments of medical devices or pharmaceuticals. Establishing a high-quality registry requires meticulous planning and adherence to established guidelines. Professional organizations, such as the European Society of Cardiology (ESC) and the American Heart Association (AHA), offer detailed guidance documents for setting up and managing registries. Additionally, various checklists and frameworks exist to evaluate and ensure registry quality, aiding researchers in optimizing data reliability and utility. With advancements in digital health, the potential of electronic health records (EHRs) to complement or replace traditional registries is increasingly explored. EHRs offer a dynamic, real-time data collection mechanism, reducing redundancy and operational costs while maintaining data accuracy. However, considerations around interoperability, data privacy, and standardization remain critical in leveraging EHRs for registry purposes.
Keywords: Review; cardiology; congenital heart disease (CHD); observational study; registry.
Copyright © 2025 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-2024-579/coif). The series “Current Management Aspects in Adult Congenital Heart Disease (ACHD): Part VI” was commissioned by the editorial office without any funding or sponsorship. H.K. serves as the Guest Editor of the series and is a Member of the COMPERA steering board. The authors have no other conflicts of interest to declare.
Similar articles
-
Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency.Eur Heart J Qual Care Clin Outcomes. 2023 Feb 28;9(2):109-118. doi: 10.1093/ehjqcco/qcad009. Eur Heart J Qual Care Clin Outcomes. 2023. PMID: 36746430
-
PATHFINDER-CHD: prospective registry on adults with congenital heart disease, abnormal ventricular function, and/or heart failure as a foundation for establishing rehabilitative, prehabilitative, preventive, and health-promoting measures: rationale, aims, design and methods.BMC Cardiovasc Disord. 2024 Mar 26;24(1):181. doi: 10.1186/s12872-024-03833-y. BMC Cardiovasc Disord. 2024. PMID: 38532336 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Bridging ideal studies and real-world practice: the potential role of real-world evidence in reproductive medicine.Reprod Biomed Online. 2025 Apr;50(4):104807. doi: 10.1016/j.rbmo.2025.104807. Reprod Biomed Online. 2025. PMID: 40287211 Review.
-
Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.J Pharm Pharm Sci. 2024 Feb 28;27:12302. doi: 10.3389/jpps.2024.12302. eCollection 2024. J Pharm Pharm Sci. 2024. PMID: 38481726 Free PMC article.
Cited by
-
Overweight and Obesity in Adults with Congenital Heart Disease and Heart Failure: Real-World Evidence from the PATHFINDER-CHD Registry.J Clin Med. 2025 Jun 27;14(13):4561. doi: 10.3390/jcm14134561. J Clin Med. 2025. PMID: 40648934 Free PMC article.
References
-
- Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:1494-563. 10.1016/j.jacc.2018.08.1028 - DOI - PubMed
-
- Kaemmerer H, Baldus H, Baumgartner H, et al. Adults with congenital heart defects”: current challenges in medical care. Part I: the problem, structure of care, heart failure, cardiac arrhythmias. Position paper of the German Cardiac Society [Original in German]. Kardiologie 2023;17:219-33. 10.1007/s12181-023-00616-1 - DOI
Publication types
LinkOut - more resources
Full Text Sources